Recce inks Australia and NZ licensing deal for diabetic foot infections gel

• Arrotex Pharmaceuticals granted exclusive rights to register and commercialise Recce’s topic gel R327G for diabetic foot infections in Australia and NZ
• Under the deal Recce will receive a significant profit share of gross margin from product sales of R327G
• The gel is in registrational Phase III trials for diabetic foot infections in Australia and Indonesia

Special Report: Recce Pharmaceuticals has signed an exclusive licensing and commercialisation agreement with Arrotex Pharmaceuticals for its RECCE 327 (R327G) topical gel to treat diabetic foot infections (DFIs) in Australia and New Zealand.

Under the deal, Arrotex will obtain exclusive commercialisation rights for R327G in Australia and New Zealand.

Recce Pharmaceuticals (ASX:RCE) will remain the exclusive manufacturer and supplier of R327G and receive a significant profit share of gross margin from sales.

RCE is developing a new class of synthetic anti-infectives designed to address serious infections, including those caused by antibiotic-resistant bacteria.

Part of DBG Health, Arrotex describes itself as Australia’s largest and most diversified pharmaceutical company, offering an extensive range of prescription medicines across therapeutic areas.

Addressing significant diabetes complication

DFIs are bacterial infections involving the skin, soft tissue or bone of the foot in people with diabetes.

They commonly develop in association with diabetes-related foot ulcers and can be difficult to treat because of impaired circulation, neuropathy and antimicrobial resistance.

RCE said if not effectively managed, DFIs may lead to hospitalisation, surgery or amputation.

In Australia, ~50,000 people are estimated to be living with a diabetes-related foot ulcer, with about 300,000 more considered at risk.

R327 is RCE’s synthetic anti-infective being developed for serious and potentially life-threatening infections caused by Gram-positive and Gram-negative bacteria, including antibiotic-resistant pathogens.

The topical gel formulation R327G is being studied for bacterial wounds, burns and skin infections.

It is in registrational Phase III clinical development for DFIs in Australia and Indonesia.

‘Innovative approach’ to DFI treatment

CEO James Graham said RCE looks forward to working with Arrotex to address a serious area of unmet medical need.

“This agreement brings together Recce’s anti-infective development platform and Arrotex’s established regulatory, market access and commercial capabilities in Australia and New Zealand,” he said.

“Arrotex is a leading regional partner with the infrastructure and healthcare relationships needed to prepare R327G for the market, subject to successful clinical development and regulatory approval.”

Arrotex Chief Medical Officer Dr Melinda Munns said R327G offered a new approach to dealing with a serious complication of diabetes.

“We are pleased to partner with Recce to help advance a potential new treatment for diabetic foot infections in Australia and New Zealand,” she said.

“On approval, we expect R327G will represent an innovative approach to a serious and costly complication of diabetes, and this partnership aligns strongly with our commitment to bring differentiated medicines to patients with significant unmet needs.”

This article was developed in collaboration with Recce Pharmaceuticals, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

The post Recce inks Australia and NZ licensing deal for diabetic foot infections gel appeared first on Stockhead.